Lakefront Biotherapeutics (LKFT) Total Liabilities (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Total Liabilities for 13 consecutive years, with $135.5 million the latest figure, recorded in Q1 2026.

• Quarterly Total Liabilities fell 90.66% year-over-year to $135.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $135.5 million (down 90.66% YoY) and the FY2025 annual result came in at $194.2 million, down 86.22% from the prior year.
• Total Liabilities slipped to $135.5 million in Q1 2026 per LKFT's latest filing, from $194.2 million in the prior quarter.
• Over the last five years, Total Liabilities for LKFT reached as high as $2.8 billion in Q1 2022 and fell as low as $135.5 million in Q1 2026.
• A 5-year average of $1.6 billion and a median of $1.5 billion in 2024 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2025 — Total Liabilities slipped 13.12% — and 2026, when it plunged 90.66%.
• Year by year, Total Liabilities stood at $2.5 billion in 2022, then retreated by 29.28% to $1.8 billion in 2023, then declined by 20.68% to $1.4 billion in 2024, then slumped by 86.22% to $194.2 million in 2025, then tumbled by 30.23% to $135.5 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $135.5 million, $194.2 million, and $1.2 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.